Levodopa-carbidopa intestinal gel in the treatment of patients with parkinson disease: Results of a 12-month open studySkoromets A.,
Odinak M.,
Yakupov E.,
Litvinenko I.,
Zalyalova Z.,
Timofeeva A.,
Kirtaev S.,
Bogdanov R.,
Agafina A.,
Chatamra K.,
Robieson W.,
Benesh J.,
Latypova G.,
Ershova M.,
Illarioshkin S. of Parkinson disease (PD) who did not respond adequately to treatment with oral drugs. Material and methods:
A Levodopa-carbidopa intestinal gel in the treatment of patients with parkinson disease: Results of a 12-month open studySkoromets A.,
Odinak M.,
Yakupov E.,
Litvinenko I.,
Zalyalova Z.,
Timofeeva A.,
Kirtaev S.,
Bogdanov R.,
Agafina A.,
Chatamra K.,
Robieson W.,
Benesh J.,
Latypova G.,
Ershova M.,
Illarioshkin S. of Parkinson disease (PD) who did not respond adequately to treatment with oral drugs. Material and methods:
A Efficacy and safety of favipiravir in a complex therapy of mild to moderate COVID-19 of SARS-CoV-2. Patients were randomly assigned in
a 2:1 ratio to receive either favipiravir (1800 mg BID